{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:32:32Z","timestamp":1784835152497,"version":"3.55.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T00:00:00Z","timestamp":1537574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007464","name":"Torsten S\u00f6derbergs Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007464","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006129","name":"Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010815","name":"Stiftelsen f\u00f6r Gamla Tj\u00e4narinnor","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010815","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Foundation for Research on Alzheimer"},{"name":"Swedish state support for Clinical Research"},{"name":"Alzheimer's Research UK"},{"name":"Leonard Wolfson Centre for Experimental Neurology"},{"name":"UK dementia Research Institute at UCL"},{"name":"Reta Lila Weston Institute for Neurological Studies"},{"name":"Medical Research Counsil"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00401-018-1910-3","type":"journal-article","created":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T09:14:20Z","timestamp":1537607660000},"page":"89-102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4481-508X","authenticated-orcid":false,"given":"Hlin","family":"Kvartsberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammaryn","family":"Lashley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina E.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Brinkmalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C.","family":"Cullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kina","family":"H\u00f6glund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Portelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,22]]},"reference":[{"key":"1910_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jalz.2016.03.001","volume":"12","author":"Alzheimer\u2019s Association","year":"2016","unstructured":"Alzheimer\u2019s Association (2016) 2016 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 12:459\u2013509","journal-title":"Alzheimers Dement"},{"key":"1910_CR2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.bbamem.2006.01.012","volume":"1758","author":"B Aussedat","year":"2006","unstructured":"Aussedat B, Sagan S, Chassaing G, Bolbach G, Burlina F (2006) Quantification of the efficiency of cargo delivery by peptidic and pseudo-peptidic Trojan carriers using MALDI-TOF mass spectrometry. Biochim Biophys Acta 1758:375\u2013383. https:\/\/doi.org\/10.1016\/j.bbamem.2006.01.012","journal-title":"Biochim Biophys Acta"},{"key":"1910_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0014-5793(01)03239-2","volume":"513","author":"M Bahler","year":"2002","unstructured":"Bahler M, Rhoads A (2002) Calmodulin signaling via the IQ motif. FEBS Lett 513:107\u2013113","journal-title":"FEBS Lett"},{"key":"1910_CR4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0021-9258(18)52425-X","volume":"266","author":"J Baudier","year":"1991","unstructured":"Baudier J, Deloulme JC, Van Dorsselaer A, Black D, Matthes HW (1991) Purification and characterization of a brain-specific protein kinase C substrate, neurogranin (p17). Identification of a consensus amino acid sequence between neurogranin and neuromodulin (GAP43) that corresponds to the protein kinase C phosphorylation site and the calmodulin-binding domain. J Biol Chem 266:229\u2013237","journal-title":"J Biol Chem"},{"key":"1910_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13024-018-0279-z","volume":"13","author":"B Becker","year":"2018","unstructured":"Becker B, Nazir FH, Brinkmalm G, Camporesi E, Kvartsberg H, Portelius E et al (2018) Alzheimer-associated cerebrospinal fluid fragments of neurogranin are generated by Calpain-1 and prolyl endopeptidase. Mol Neurodegener 13:47. https:\/\/doi.org\/10.1186\/s13024-018-0279-z","journal-title":"Mol Neurodegener"},{"key":"1910_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/0891988710383571","volume":"23","author":"LM Bekris","year":"2010","unstructured":"Bekris LM, Yu CE, Bird TD, Tsuang DW (2010) Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol 23:213\u2013227. https:\/\/doi.org\/10.1177\/0891988710383571","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"1910_CR7","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1212\/01.wnl.0000219668.47116.e6","volume":"66","author":"DA Bennett","year":"2006","unstructured":"Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC et al (2006) Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66:1837\u20131844. https:\/\/doi.org\/10.1212\/01.wnl.0000219668.47116.e6","journal-title":"Neurology"},{"key":"1910_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/BF01273157","volume":"103","author":"K Blennow","year":"1996","unstructured":"Blennow K, Bogdanovic N, Alafuzoff I, Ekman R, Davidsson P (1996) Synaptic pathology in Alzheimer\u2019s disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J Neural Transm 103:603\u2013618. https:\/\/doi.org\/10.1007\/BF01273157 (Vienna)","journal-title":"J Neural Transm"},{"key":"1910_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer\u2019s disease. Lancet 368:387\u2013403. https:\/\/doi.org\/10.1016\/S0140-6736(06)69113-7","journal-title":"Lancet"},{"key":"1910_CR10","first-page":"18","volume":"2","author":"N Bogdanovic","year":"2002","unstructured":"Bogdanovic N, Davidsson P, Gottfries J, VIW B, Blennow K (2002) Regional and cellular distribution of synaptic proteins in the normal human brain. Brain Aging 2:18\u201330","journal-title":"Brain Aging"},{"key":"1910_CR11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239\u2013259","journal-title":"Acta Neuropathol"},{"key":"1910_CR12","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/jms.2987","volume":"47","author":"G Brinkmalm","year":"2012","unstructured":"Brinkmalm G, Portelius E, Ohrfelt A, Mattsson N, Persson R, Gustavsson MK et al (2012) An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid beta and amyloid precursor protein in human and cat cerebrospinal fluid. J Mass Spectrom 47:591\u2013603. https:\/\/doi.org\/10.1002\/jms.2987","journal-title":"J Mass Spectrom"},{"key":"1910_CR13","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1080\/07853890802186905","volume":"40","author":"N Brouwers","year":"2008","unstructured":"Brouwers N, Sleegers K, Van Broeckhoven C (2008) Molecular genetics of Alzheimer\u2019s disease: an update. Ann Med 40:562\u2013583. https:\/\/doi.org\/10.1080\/07853890802186905","journal-title":"Ann Med"},{"key":"1910_CR14","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1093\/hmg\/ddr381","volume":"20","author":"MJ Calkins","year":"2011","unstructured":"Calkins MJ, Manczak M, Mao P, Shirendeb U, Reddy PH (2011) Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer\u2019s disease. Hum Mol Genet 20:4515\u20134529. https:\/\/doi.org\/10.1093\/hmg\/ddr381","journal-title":"Hum Mol Genet"},{"key":"1910_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1017\/S1041610298005110","volume":"10","author":"P Davidsson","year":"1998","unstructured":"Davidsson P, Blennow K (1998) Neurochemical dissection of synaptic pathology in Alzheimer\u2019s disease. Int Psychogeriatr 10:11\u201323","journal-title":"Int Psychogeriatr"},{"key":"1910_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0022-510X(87)90057-8","volume":"78","author":"CA Davies","year":"1987","unstructured":"Davies CA, Mann DM, Sumpter PQ, Yates PO (1987) A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer\u2019s disease. J Neurol Sci 78:151\u2013164","journal-title":"J Neurol Sci"},{"key":"1910_CR17","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.jalz.2015.05.012","volume":"11","author":"A Vos De","year":"2015","unstructured":"De Vos A, Jacobs D, Struyfs H, Fransen E, Andersson K, Portelius E et al (2015) C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer\u2019s disease. Alzheimers Dement 11:1461\u20131469. https:\/\/doi.org\/10.1016\/j.jalz.2015.05.012","journal-title":"Alzheimers Dement"},{"key":"1910_CR18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ana.410270502","volume":"27","author":"ST DeKosky","year":"1990","unstructured":"DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer\u2019s disease: correlation with cognitive severity. Ann Neurol 27:457\u2013464. https:\/\/doi.org\/10.1002\/ana.410270502","journal-title":"Ann Neurol"},{"key":"1910_CR19","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s11064-009-9924-9","volume":"34","author":"F Domenico Di","year":"2009","unstructured":"Di Domenico F, Cenini G, Sultana R, Perluigi M, Uberti D, Memo M et al (2009) Glutathionylation of the pro-apoptotic protein p53 in Alzheimer\u2019s disease brain: implications for AD pathogenesis. Neurochem Res 34:727\u2013733. https:\/\/doi.org\/10.1007\/s11064-009-9924-9","journal-title":"Neurochem Res"},{"key":"1910_CR20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/iub.357","volume":"62","author":"FJ Diez-Guerra","year":"2010","unstructured":"Diez-Guerra FJ (2010) Neurogranin, a link between calcium\/calmodulin and protein kinase C signaling in synaptic plasticity. IUBMB Life 62:597\u2013606. https:\/\/doi.org\/10.1002\/iub.357","journal-title":"IUBMB Life"},{"key":"1910_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13195-015-0114-5","volume":"7","author":"J Dumurgier","year":"2015","unstructured":"Dumurgier J, Schraen S, Gabelle A, Vercruysse O, Bombois S, Laplanche JL et al (2015) Cerebrospinal fluid amyloid-beta 42\/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimers Res Ther 7:30. https:\/\/doi.org\/10.1186\/s13195-015-0114-5","journal-title":"Alzheimers Res Ther"},{"key":"1910_CR22","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1159\/000100926","volume":"23","author":"O Hansson","year":"2007","unstructured":"Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L et al (2007) Prediction of Alzheimer\u2019s disease using the CSF Abeta42\/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 23:316\u2013320. https:\/\/doi.org\/10.1159\/000100926","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1910_CR23","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1038\/emboj.2009.273","volume":"28","author":"Y Hayashi","year":"2009","unstructured":"Hayashi Y (2009) Long-term potentiation: two pathways meet at neurogranin. EMBO J 28:2859\u20132860. https:\/\/doi.org\/10.1038\/emboj.2009.273","journal-title":"EMBO J"},{"key":"1910_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13195-015-0161-y","volume":"7","author":"K Hellwig","year":"2015","unstructured":"Hellwig K, Kvartsberg H, Portelius E, Andreasson U, Oberstein TJ, Lewczuk P et al (2015) Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer\u2019s disease. Alzheimers Res Ther 7:74. https:\/\/doi.org\/10.1186\/s13195-015-0161-y","journal-title":"Alzheimers Res Ther"},{"key":"1910_CR25","doi-asserted-by":"publisher","first-page":"10660","DOI":"10.1523\/JNEUROSCI.2213-04.2004","volume":"24","author":"KP Huang","year":"2004","unstructured":"Huang KP, Huang FL, Jager T, Li J, Reymann KG, Balschun D (2004) Neurogranin\/RC3 enhances long-term potentiation and learning by promoting calcium-mediated signaling. J Neurosci 24:10660\u201310669. https:\/\/doi.org\/10.1523\/JNEUROSCI.2213-04.2004","journal-title":"J Neurosci"},{"key":"1910_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC et al (2012) National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement 8:1\u201313. https:\/\/doi.org\/10.1016\/j.jalz.2011.10.007","journal-title":"Alzheimers Dement"},{"key":"1910_CR27","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB et al (2018) NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 14:535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimers Dement"},{"key":"1910_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/acn3.266","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Hertze J, Zetterberg H, Landqvist Waldo M, Santillo A, Blennow K et al (2016) Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer\u2019s disease. Ann Clin Transl Neurol 3:12\u201320. https:\/\/doi.org\/10.1002\/acn3.266","journal-title":"Ann Clin Transl Neurol"},{"key":"1910_CR29","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1007\/s12035-014-9053-6","volume":"53","author":"PK Kamat","year":"2016","unstructured":"Kamat PK, Kalani A, Rai S, Swarnkar S, Tota S, Nath C et al (2016) Mechanism of oxidative stress and synapse dysfunction in the pathogenesis of Alzheimer\u2019s disease: understanding the therapeutics strategies. Mol Neurobiol 53:648\u2013661. https:\/\/doi.org\/10.1007\/s12035-014-9053-6","journal-title":"Mol Neurobiol"},{"key":"1910_CR30","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/jamaneurol.2015.1867","volume":"72","author":"MI Kester","year":"2015","unstructured":"Kester MI, Teunissen CE, Crimmins DL, Herries EM, Ladenson JH, Scheltens P et al (2015) Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol 72:1275\u20131280. https:\/\/doi.org\/10.1001\/jamaneurol.2015.1867","journal-title":"JAMA Neurol"},{"key":"1910_CR31","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1093\/jnen\/62.11.1087","volume":"62","author":"DS Knopman","year":"2003","unstructured":"Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ et al (2003) Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 62:1087\u20131095","journal-title":"J Neuropathol Exp Neurol"},{"key":"1910_CR32","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jalz.2014.10.009","volume":"11","author":"H Kvartsberg","year":"2015","unstructured":"Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Ohrfelt A, Andersson K et al (2015) Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer\u2019s disease. Alzheimers Dement 11:1180\u20131190. https:\/\/doi.org\/10.1016\/j.jalz.2014.10.009","journal-title":"Alzheimers Dement"},{"key":"1910_CR33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13195-015-0124-3","volume":"7","author":"H Kvartsberg","year":"2015","unstructured":"Kvartsberg H, Portelius E, Andreasson U, Brinkmalm G, Hellwig K, Lelental N et al (2015) Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer\u2019s disease patients and healthy controls. Alzheimers Res Ther 7:40. https:\/\/doi.org\/10.1186\/s13195-015-0124-3","journal-title":"Alzheimers Res Ther"},{"key":"1910_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3233\/JAD-140771","volume":"43","author":"P Lewczuk","year":"2015","unstructured":"Lewczuk P, Lelental N, Spitzer P, Maler JM, Kornhuber J (2015) Amyloid-beta 42\/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer\u2019s disease: validation of two novel assays. J Alzheimers Dis 43:183\u2013191. https:\/\/doi.org\/10.3233\/JAD-140771","journal-title":"J Alzheimers Dis"},{"key":"1910_CR35","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/hmg\/ddl066","volume":"15","author":"M Manczak","year":"2006","unstructured":"Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH (2006) Mitochondria are a direct site of A beta accumulation in Alzheimer\u2019s disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15:1437\u20131449. https:\/\/doi.org\/10.1093\/hmg\/ddl066","journal-title":"Hum Mol Genet"},{"key":"1910_CR36","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/BF00293464","volume":"81","author":"E Masliah","year":"1991","unstructured":"Masliah E, Hansen L, Albright T, Mallory M, Terry RD (1991) Immunoelectron microscopic study of synaptic pathology in Alzheimer\u2019s disease. Acta Neuropathol 81:428\u2013433","journal-title":"Acta Neuropathol"},{"key":"1910_CR37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1212\/WNL.56.1.127","volume":"56","author":"E Masliah","year":"2001","unstructured":"Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW et al (2001) Altered expression of synaptic proteins occurs early during progression of Alzheimer\u2019s disease. Neurology 56:127\u2013129","journal-title":"Neurology"},{"key":"1910_CR38","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.15252\/emmm.201606540","volume":"8","author":"N Mattsson","year":"2016","unstructured":"Mattsson N, Insel PS, Palmqvist S, Portelius E, Zetterberg H, Weiner M et al (2016) Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer\u2019s disease. EMBO Mol Med 8:1184\u20131196. https:\/\/doi.org\/10.15252\/emmm.201606540","journal-title":"EMBO Mol Med"},{"key":"1910_CR39","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s disease. Neurology 34:939\u2013944","journal-title":"Neurology"},{"key":"1910_CR40","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH et al (2011) The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7:263\u2013269. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005","journal-title":"Alzheimers Dement"},{"key":"1910_CR41","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1046\/j.1471-4159.2001.00646.x","volume":"79","author":"N Mons","year":"2001","unstructured":"Mons N, Enderlin V, Jaffard R, Higueret P (2001) Selective age-related changes in the PKC-sensitive, calmodulin-binding protein, neurogranin, in the mouse brain. J Neurochem 79:859\u2013867","journal-title":"J Neurochem"},{"key":"1910_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW et al (2012) National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol 123:1\u201311. https:\/\/doi.org\/10.1007\/s00401-011-0910-3","journal-title":"Acta Neuropathol"},{"key":"1910_CR43","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbadis.2011.10.003","volume":"1822","author":"CB Pocernich","year":"2012","unstructured":"Pocernich CB, Butterfield DA (2012) Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochim Biophys Acta 1822:625\u2013630. https:\/\/doi.org\/10.1016\/j.bbadis.2011.10.003","journal-title":"Biochim Biophys Acta"},{"key":"1910_CR44","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000369465","volume":"15","author":"E Portelius","year":"2015","unstructured":"Portelius E, Lashley T, Westerlund A, Persson R, Fox NC, Blennow K et al (2015) Brain amyloid-beta fragment signatures in pathological ageing and Alzheimer\u2019s disease by hybrid immunoprecipitation mass spectrometry. Neurodegener Dis 15:50\u201357. https:\/\/doi.org\/10.1159\/000369465","journal-title":"Neurodegener Dis"},{"key":"1910_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-018-1851-x","author":"E Portelius","year":"2018","unstructured":"Portelius E, Olsson B, H\u00f6glund K, Cullen NC, Kvartsberg H, Andreasson U et al (2018) Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathol. https:\/\/doi.org\/10.1007\/s00401-018-1851-x","journal-title":"Acta Neuropathol"},{"key":"1910_CR46","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1093\/brain\/awv267","volume":"138","author":"E Portelius","year":"2015","unstructured":"Portelius E, Zetterberg H, Skillback T, Tornqvist U, Andreasson U, Trojanowski JQ et al (2015) Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer\u2019s disease. Brain 138:3373\u20133385. https:\/\/doi.org\/10.1093\/brain\/awv267","journal-title":"Brain"},{"key":"1910_CR47","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/0197-4580(91)90006-6","volume":"12","author":"JL Price","year":"1991","unstructured":"Price JL, Davis PB, Morris JC, White DL (1991) The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimers-disease. Neurobiol Aging 12:295\u2013312. https:\/\/doi.org\/10.1016\/0197-4580(91)90006-6","journal-title":"Neurobiol Aging"},{"key":"1910_CR48","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.molmed.2007.12.002","volume":"14","author":"PH Reddy","year":"2008","unstructured":"Reddy PH, Beal MF (2008) Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer\u2019s disease. Trends Mol Med 14:45\u201353. https:\/\/doi.org\/10.1016\/j.molmed.2007.12.002","journal-title":"Trends Mol Med"},{"key":"1910_CR49","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3233\/JAD-2005-7203","volume":"7","author":"PH Reddy","year":"2005","unstructured":"Reddy PH, Mani G, Park BS, Jacques J, Murdoch G, Whetsell W Jr et al (2005) Differential loss of synaptic proteins in Alzheimer\u2019s disease: implications for synaptic dysfunction. J Alzheimers Dis 7:103\u2013117 (discussion 173\u2013180)","journal-title":"J Alzheimers Dis"},{"key":"1910_CR50","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1096\/fasebj.11.5.9141499","volume":"11","author":"AR Rhoads","year":"1997","unstructured":"Rhoads AR, Friedberg F (1997) Sequence motifs for calmodulin recognition. FASEB J 11:331\u2013340","journal-title":"FASEB J"},{"key":"1910_CR51","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1093\/brain\/awu190","volume":"137","author":"JL Robinson","year":"2014","unstructured":"Robinson JL, Molina-Porcel L, Corrada MM, Raible K, Lee EB, Lee VM et al (2014) Perforant path synaptic loss correlates with cognitive impairment and Alzheimer\u2019s disease in the oldest-old. Brain 137:2578\u20132587. https:\/\/doi.org\/10.1093\/brain\/awu190","journal-title":"Brain"},{"key":"1910_CR52","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1212\/01.wnl.0000260698.46517.8f","volume":"68","author":"SW Scheff","year":"2007","unstructured":"Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ (2007) Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 68:1501\u20131508. https:\/\/doi.org\/10.1212\/01.wnl.0000260698.46517.8f","journal-title":"Neurology"},{"key":"1910_CR53","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.neurobiolaging.2005.09.012","volume":"27","author":"SW Scheff","year":"2006","unstructured":"Scheff SW, Price DA, Schmitt FA, Mufson EJ (2006) Hippocampal synaptic loss in early Alzheimer\u2019s disease and mild cognitive impairment. Neurobiol Aging 27:1372\u20131384. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2005.09.012","journal-title":"Neurobiol Aging"},{"key":"1910_CR54","doi-asserted-by":"publisher","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"A Serrano-Pozo","year":"2011","unstructured":"Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1:a006189. https:\/\/doi.org\/10.1101\/cshperspect.a006189","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1910_CR55","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1073\/pnas.0608332104","volume":"104","author":"J Shen","year":"2007","unstructured":"Shen J, Kelleher RJ 3rd (2007) The presenilin hypothesis of Alzheimer\u2019s disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci USA 104:403\u2013409. https:\/\/doi.org\/10.1073\/pnas.0608332104","journal-title":"Proc Natl Acad Sci USA"},{"key":"1910_CR56","doi-asserted-by":"publisher","first-page":"470","DOI":"10.2174\/156720510791383796","volume":"7","author":"PE Spies","year":"2010","unstructured":"Spies PE, Slats D, Sjogren JM, Kremer BP, Verhey FR, Rikkert MG et al (2010) The cerebrospinal fluid amyloid beta42\/40 ratio in the differentiation of Alzheimer\u2019s disease from non-Alzheimer\u2019s dementia. Curr Alzheimer Res 7:470\u2013476","journal-title":"Curr Alzheimer Res"},{"key":"1910_CR57","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.neuron.2014.05.004","volume":"82","author":"TL Spires-Jones","year":"2014","unstructured":"Spires-Jones TL, Hyman BT (2014) The intersection of amyloid beta and tau at synapses in Alzheimer\u2019s disease. Neuron 82:756\u2013771. https:\/\/doi.org\/10.1016\/j.neuron.2014.05.004","journal-title":"Neuron"},{"key":"1910_CR58","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1097\/00005072-199708000-00011","volume":"56","author":"CI Sze","year":"1997","unstructured":"Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ (1997) Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol 56:933\u2013944","journal-title":"J Neuropathol Exp Neurol"},{"key":"1910_CR59","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jamaneurol.2016.0086","volume":"73","author":"R Tarawneh","year":"2016","unstructured":"Tarawneh R, D\u2019Angelo G, Crimmins D, Herries E, Griest T, Fagan AM et al (2016) Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease. JAMA Neurol 73:561\u2013571. https:\/\/doi.org\/10.1001\/jamaneurol.2016.0086","journal-title":"JAMA Neurol"},{"key":"1910_CR60","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791\u20131800","journal-title":"Neurology"},{"key":"1910_CR61","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.brainres.2010.09.073","volume":"1362","author":"A Thorsell","year":"2010","unstructured":"Thorsell A, Bjerke M, Gobom J, Brunhage E, Vanmechelen E, Andreasen N et al (2010) Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer\u2019s disease. Brain Res 1362:13\u201322. https:\/\/doi.org\/10.1016\/j.brainres.2010.09.073","journal-title":"Brain Res"},{"key":"1910_CR62","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/j.1471-4159.2006.04404.x","volume":"101","author":"J Wiltfang","year":"2007","unstructured":"Wiltfang J, Esselmann H, Bibl M, Hull M, Hampel H, Kessler H et al (2007) Amyloid beta peptide ratio 42\/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J Neurochem 101:1053\u20131059. https:\/\/doi.org\/10.1111\/j.1471-4159.2006.04404.x","journal-title":"J Neurochem"},{"key":"1910_CR63","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrn1647","volume":"6","author":"ZG Xia","year":"2005","unstructured":"Xia ZG, Storm DR (2005) The role of calmodulin as a signal integrator for synaptic plasticity. Nat Rev Neurosci 6:267\u2013276. https:\/\/doi.org\/10.1038\/nrn1647","journal-title":"Nat Rev Neurosci"},{"key":"1910_CR64","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0168-0102(01)00201-2","volume":"39","author":"VV Zakharov","year":"2001","unstructured":"Zakharov VV, Mosevitsky MI (2001) Site-specific calcium-dependent proteolysis of neuronal protein GAP-43. Neurosci Res 39:447\u2013453","journal-title":"Neurosci Res"},{"key":"1910_CR65","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1038\/emboj.2009.236","volume":"28","author":"L Zhong","year":"2009","unstructured":"Zhong L, Cherry T, Bies CE, Florence MA, Gerges NZ (2009) Neurogranin enhances synaptic strength through its interaction with calmodulin. EMBO J 28:3027\u20133039. https:\/\/doi.org\/10.1038\/emboj.2009.236","journal-title":"EMBO J"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00401-018-1910-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-018-1910-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-018-1910-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T12:06:15Z","timestamp":1662120375000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00401-018-1910-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,22]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["1910"],"URL":"https:\/\/doi.org\/10.1007\/s00401-018-1910-3","relation":{},"ISSN":["0001-6322","1432-0533"],"issn-type":[{"value":"0001-6322","type":"print"},{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,22]]},"assertion":[{"value":"6 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"HZ is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg, has served at advisory boards of Eli Lilly, Roche Diagnostics and Wave and has received travel support from TEVA. KB has served as a consultant or at advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Pfizer, and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. KH has served as consultant for Eisai and Abbvie.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}